awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30C
Q47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30C
No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
P2860
Q47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ff146363137dd4db0edd5288a9ace7e9b88f3ba9
P2860
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm